Overall, 82.2% of patients had prior tumor surgery and 82.2% of patients had received prior targeted therapies (bevacizumab, 53.9%; EGFR-I, 13.2%; both, 15.1%) (Table 1). The gene discussed is EGFR; the disease is neoplasm.